EUCTR2009-013157-15-PT进行中（未招募）1 期
A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial. - CAROLINA
nilfarma - União Internacional de Lab. Farmacêuticos, Lda.0 个研究点目标入组 10,606 人开始时间: 2010年9月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10,606
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Documented diagnosis of T2DM and concurrently 1) insufficient glycaemic control and 2) a high risk of CV events prior to informed consent
- •1) Insufficient glycaemic control (at Visit 1a) defined as:
- •a) HbA1c 6.5 - 8.5% (48 - 69 mmol/mol) while patient is treatment naïve (if intolerant or contra-indicated to first line anti-diabetic treatment) or treated with:
- •- metformin monotherapy, or
- •- alpha-glucosidase inhibitor monotherapy (e.g. acarbose, voglibose), or
- •- metformin + alpha-glucosidase inhibitor (e.g. acarbose, voglibose), or
- •b) HbA1c 6.5 - 7.5% (48 - 58 mmol/mol) while patient is treated with
- •- sulphonylurea (SU) monotherapy, or
- •- glinide monotherapy (e.g. repaglinide, nateglinide), or
- •- metformin + SU (combination maximal up to 5 years), or
- •- metformin + glinide (combination maximal up to 5 years) or
- •- alpha-glucosidase inhibitor + SU (combination maximal up to 5 years),
- •- alpha-glucosidase inhibitor + glinide (combination maximal up to 5 years)
- •2) High risk of CV events defined as any one (or more) of A), B), C) or D):
- •A) Previous Vascular Disease:
- •- Myocardial infarction (> 6 weeks prior to informed consent)
- •- Documented coronary artery disease or disease (=50% luminal diameter narrowing of left main coronary artery or =50% in at least two major coronary arteries in angiogram)
- •- Percutaneous Coronary Intervention (PCI) > 6 weeks prior informed consent
- •- Coronary Artery By-pass Grafting (CABG) > 4 years prior to informed consent or with recurrent angina following surgery
- •- Ischemic or hemorrhagic stroke (> 3 months prior to informed consent)
- •- Peripheral occlusive arterial disease (previous limb bypass surgery, stenting or percutaneous transluminal angioplasty; previous limb or foot amputation due to circulatory insufficiency, angiographic or ultrasound detected significant vessel stenosis (>50%) of major limb arteries (common iliac artery, internal iliac artery, external iliac artery, femoral artery, popliteal artery), history of intermittent claudication, with an ankle: arm blood pressure ratio < 0.90 on at least one side).
- •B) Evidence of vascular related end-organ damage:
- •- Moderately impaired renal function (as defined by modified diet of renal disease (MDRD) formula) with estimated glomerular filtration rate [eGFRF]) 30-59 mL/min/1.73 m2
- •- Random spot urinary albumin:creatinine ratio = 30 µg/mg (= 3.4 mg/mmol) in two of three unrelated specimens in previous 12 months prior Visit 1a
- •- Proliferative retinopathy defined as retinal neovascularisation or previous retinal laser coagulation therapy.
- •C) Age = 70 years (at Visit 1a)
- •D) At least two of the following CV risk factors:
- •- Type 2 diabetes mellitus duration > 10 years at Visit 1a.
- •- Systolic blood pressure (SBP) > 140 mmHg (or on at least one blood pressure lowering treatment at Visit 1a)
- •- Current daily cigarette smoking
排除标准
- •Type 1 diabetes mellitus
- •Any history and/or current treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone, GLP-1 analogue/agonists, DPP-IV inhibitors or any insulin) prior to informed consent. Note 1: This also includes clinical trials where these antidiabetic drugs have been provided to the patient. Note 2: previous short term use of any insulin (up to two consecutive weeks) is allowed (e.g. during hospitalisation) if taken at least 8 weeks prior informed consent.
- •Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) within 3 months prior to informed consent
- •Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3
- •mmol/L) after an overnight fast during placebo run-in and confirmed by
- •a second measurement (not on the same day)
- •Any previous (or planned within next 12 months) bariatric surgery (open or laparascopic) or intervention (gastric sleeve)
- •Current treatment with systemic corticosteroids at time of informed consent or pre-planned initiation of such therapy Note: inhaled use of steroids (e.g. for asthma/COPD) is no exclusion criterion, as this does not cause systemic steroid action
- •Change in dose of thyroid hormones within 6 weeks prior informed consent
- •Active liver disease or impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at visit 1a
- •Pre-planned coronary artery re-vascularization (PCI, CABG) within next 6 months after V1a or any previous PCI and/or CABG = 6 weeks prior informed consent
- •Known hypersensitivity or allergy to the investigational product or its excipients, or glimepiride (or the SU class).
- •Known hypersensitivity or allergy to the investigational product or its
- •excipients, or glimepiride (or the SU class)
- •Inappropriateness of glimepiride treatment for renal safety issues or other issues (e.g. allergy) according to local prescribing information
- •Pre-menopausal women (last menstruation = 1 year prior to informed
- •consent) who are nursing or pregnant,or are of child-bearing potential
- •and are not practicing an acceptable method of birth control (acceptable methods of birth control include tubal ligation, transdermal patch, intrauterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence (if allowed by local authorities), double barrier method and vasectomised partner) or do not plan to continue using acceptable method of birth control throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
- •Congestive heart failure of NYHA class III or IV
- •Acute or chronic metabolic acidosis (present condition in patient history)
- •Hereditary galactose intolerance
- •Alcohol or drug abuse within the 3 months prior to informed consent
- •that would interfere with trial participation
- •Participation in another trial with an investigational drug given within 2 months prior to informed consent
- •Patients considered unreliable by the investigat
研究者
相似试验
进行中（未招募）
1 期
A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial. - CAROLINAPatients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study.MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-013157-15-FIBoehringer Ingelheim Pharma GmbH & Co. KG6,000
进行中（未招募）
1 期
A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial. - CAROLINAPatients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV eventsMedDRA version: 9.1Level: LLTClassification code 10045242EUCTR2009-013157-15-ITBOEHRINGER ING.10,606
进行中（未招募）
1 期
CAROLINA: Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients With Type 2 DiabetesEUCTR2009-013157-15-DEBoehringer Ingelheim Pharma GmbH & Co. KG10,606
进行中（未招募）
1 期
A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial. - CAROLINAEUCTR2009-013157-15-ESBoehringer Ingelheim España, S.A.6,000
进行中（未招募）
1 期
CAROLINA: Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients With Type 2 DiabetesEUCTR2009-013157-15-GBBoehringer Ingelheim Ltd10,606